# OnCo record nct07054567 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct07054567/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct07054567", "NCT07054567" ;
  schema:name "A Study of BL-B01D1 + Pembrolizumab ± Bevacizumab in Patients With Recurrent or Metastatic Cervical Cancer and Endometrial Cancer"@en ;
  schema:description "A phase 2 trial of Izalontamab brengitecan, Pembrolizumab, Bevacizumab in cervical cancer and endometrial cancer, run by Sichuan Baili Pharmaceutical Co., Ltd., now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct07054567/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT07054567> ;
  onco:status "recruiting" ;
  onco:tag "ctgov-ingest" ;
  onco:phase "2" ;
  schema:startDate "2025-08-21" ;
  onco:cancers <https://onco.cc/cancers/cervical/>, <https://onco.cc/cancers/endometrial/>, <https://onco.cc/cancers/recurrent-metastatic-cervical-cancer/>, <https://onco.cc/cancers/advanced-recurrent-endometrial-cancer/> ;
  onco:technologies <https://onco.cc/technologies/antiangiogenic/>, <https://onco.cc/technologies/checkpoint-inhibitor/>, <https://onco.cc/technologies/monoclonal-antibody/> ;
  onco:drugs <https://onco.cc/drugs/izalontamab-brengitecan/>, <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/bevacizumab/> ;
  onco:companies <https://onco.cc/companies/systimmune/> .